RSV Vaccines Deliver 80% Shield Against Hospitalization in 14.8 Million Seniors, FDA Study Confirms

FDA researchers confirmed that RSV vaccines cut hospitalization and death risk by roughly 80% in real-world conditions — a result that should silence lingering doubts about whether these shots work outside controlled clinical trials.

The landmark study, published September 18 in JAMA Network Open, tracked 14.8 million seniors aged 60 and older during the first full season after the two RSV vaccines — made by GlaxoSmithKline and Pfizer — hit the market in 2023....